Received: from PAXPR02MB7959.eurprd02.prod.outlook.com (2603:10a6:102:274::14) by DB9PR02MB7817.eurprd02.prod.outlook.com with HTTPS; Thu, 16 Jul 2026 12:33:35 +0000 Received: from GVXPR02MB12202.eurprd02.prod.outlook.com (2603:10a6:150:318::18) by PAXPR02MB7959.eurprd02.prod.outlook.com (2603:10a6:102:274::14) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.202.19; Thu, 16 Jul 2026 12:33:32 +0000 Received: from GVXPR02MB12202.eurprd02.prod.outlook.com ([fe80::7e68:6b0b:67d4:d05f]) by GVXPR02MB12202.eurprd02.prod.outlook.com ([fe80::7e68:6b0b:67d4:d05f%2]) with mapi id 15.21.0223.008; Thu, 16 Jul 2026 12:33:31 +0000 From: "Andrus Varki - RA" To: "Info - SOM" Cc: =?utf-8?Q?K=C3=A4rolin_Jenas_-_RA?= References: <0b1142f2de5b4ee9b77a206ee9671966@ravimiamet.ee> In-Reply-To: Subject: =?utf-8?Q?Vs:_Eeln=C3=B5u_edastamine_koosk=C3=B5last?= =?utf-8?Q?amiseks_ja_arvamuse_avaldamiseks?= Date: Thu, 16 Jul 2026 15:33:31 +0300 Keywords: ly Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_0054_01DD1539.FD80AA90" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQIOkpl4/ke9+WNmGnvinYgaN9pG2wEidV1AAvAO1mEBgZBMcAI+CNbTAO+NVD0CDMzEsQJQEHqMAmmhbPsBkr31NQKV9MT7Ab1gMkI= Authentication-Results: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; X-MS-Exchange-Organization-ExpirationStartTime: 16 Jul 2026 12:33:32.1219 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: daa2089c-682e-41a8-e1e1-08dee3367258 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-PublicTrafficType: Email X-MS-TrafficTypeDiagnostic: GVXPR02MB12202:EE_|PAXPR02MB7959:EE_|DB9PR02MB7817:EE_ X-MS-Exchange-Organization-AuthSource: GVXPR02MB12202.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Internal X-MS-Office365-Filtering-Correlation-Id: daa2089c-682e-41a8-e1e1-08dee3367258 X-MS-Exchange-AtpMessageProperties: SA X-MS-Exchange-Organization-SCL: 1 X-Microsoft-Antispam: BCL:0;ARA:13230040|366016|31052699007|39142699007|23010399003|11063799006|56012099006|4143699003|8096899003|22082099003|18002099003|55112099003|13003099007|10067099003|41050700001; X-Forefront-Antispam-Report: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GVXPR02MB12202.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(366016)(31052699007)(39142699007)(23010399003)(11063799006)(56012099006)(4143699003)(8096899003)(22082099003)(18002099003)(55112099003)(13003099007)(10067099003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 16 Jul 2026 12:33:31.9297 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: daa2089c-682e-41a8-e1e1-08dee3367258 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthSource: GVXPR02MB12202.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-FromEntityHeader: Hosted X-MS-Exchange-Transport-CrossTenantHeadersStamped: PAXPR02MB7959 X-MS-Exchange-Transport-EndToEndLatency: 00:00:03.9719738 X-MS-Exchange-Processed-By-BccFoldering: 15.21.0223.005 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 Content-Language: et x-ms-exchange-organization-originalclientipaddress: 45.156.32.33 x-ms-exchange-organization-originalserveripaddress: 2603:10a6:150:318::18 X-MS-Has-Attach: X-MS-TNEF-Correlator: acceptlanguage: et-EE, en-US X-OlkEid: 0000000033F4068251E5764083FB7241D8AC8008070034AD76187591974DBF6C4F76951C873A0100020000000000EE036A86AA193F47AA713E32FE8F2E570000000012B200001CD9F42F5DA55B42BDE8F7E8B5430E83 X-CodeTwoProcessed: true X-MS-Exchange-Organization-AuthMechanism: 04 msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-07-16T12:33:31.506Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; x-codetwo-clientsignature-inserted: true X-MS-Exchange-CrossTenant-MailboxType: HOSTED X-MS-Exchange-CrossTenant-UserPrincipalName: iRJFAe7rGqYh5qHVhvyrw3SF16FgS3zXP1KzxGTVDLB8d3KV8KH/wbz6hsJgDFVBpgZZeeyWltN0jafQxqBYGAigh+SaTDgY/CgmK7hToiE= This is a multipart message in MIME format. ------=_NextPart_000_0054_01DD1539.FD80AA90 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Teie:    22.06.2026 nr 1.2-3/1601-1 Meie:   15.07.2026 nr JUR-3/3768-2 Tere Ravimiamet ei ole märkuseid eelnõule, küll aga segadust tekitab seletuskiri. Seletuskirja järgi muudetakse ainult seda osa, et proviisoriõppe esimest taset ei anna edaspidi ainult ülikool vaid võib anda ka kõrgkool. Kui me nüüd oleme õigesti aru saanud, siis edaspidi ei oleks enam proviisoriõpe vaid ravimiteadus vms ja selle nominaalkestus ei ole enam 5 aastat vaid 3+2 aastat. Need muudatused käesolevate sätete muudatustes justkui ei kajastu. Muudatuste osas, et võib anda ka kõrgkool vastuväiteid ei ole, aga segadus jääb, kuidas sobitub see ülejäänud muudatuste pilti. Lugupidamisega Andrus Varki juhataja Õigusosakond Ravimiamet 737 4140 www.ravimiamet.ee Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, teavitage sellest koheselt saatjat ning kustutage e-kiri. This e-mail and any attachments transmitted may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by returning the e-mail and permanently deleting what you have received. Any dissemination or use of this information by a third person without permission is prohibited and may be illegal. ------=_NextPart_000_0054_01DD1539.FD80AA90 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable
Teie:=E2=80=82=E2=80=82=E2=80=82=E2=80=8222.06.2026 nr = 1.2-3/1601-1
Meie:=E2=80=82=E2=80=82=E2=80=8215.07.2026 nr JUR-3/3768-2


Tere

Ravimiamet ei = ole m=C3=A4rkuseid eeln=C3=B5ule, k=C3=BCll aga segadust tekitab = seletuskiri. Seletuskirja j=C3=A4rgi muudetakse ainult = seda osa, et proviisori=C3=B5ppe esimest taset ei anna edaspidi ainult = =C3=BClikool vaid v=C3=B5ib anda ka k=C3=B5rgkool. Kui me n=C3=BC=C3=BCd = oleme =C3=B5igesti aru saanud, siis edaspidi ei oleks enam = proviisori=C3=B5pe vaid ravimiteadus vms ja selle nominaalkestus ei ole = enam 5 aastat vaid 3+2 aastat. Need muudatused k=C3=A4esolevate s=C3=A4tete muudatustes justkui ei = kajastu. Muudatuste osas, et v=C3=B5ib anda ka k=C3=B5rgkool = vastuv=C3=A4iteid ei ole, aga segadus j=C3=A4=C3=A4b, kuidas sobitub see = =C3=BClej=C3=A4=C3=A4nud muudatuste pilti.



Lugupidamisega

Andrus Varki

juhataja

=C3=95igusosakond


Ravimiamet

737 4140

www.ravimiamet.ee


Selles = e-kirjas sisalduv teave (kaasa arvatud manused) on m=C3=B5eldud = ametialaseks kasutamiseks ning seda v=C3=B5ivad kasutada vaid e-kirja = adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt = v=C3=A4ljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. = Juhul, kui Te olete saanud k=C3=A4esoleva e-kirja eksituse t=C3=B5ttu, = teavitage sellest koheselt saatjat ning kustutage e-kiri. 
This e-mail and any attachments transmitted may = contain confidential and privileged information. If you are not the = intended recipient, please notify the sender immediately by = returning the e-mail and permanently deleting what you have = received. Any dissemination or use of this information by a third person without permission is = prohibited and may be illegal. 



 

------=_NextPart_000_0054_01DD1539.FD80AA90--